Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QGE031 versus placebo in refractory bullous pemphigoid
2012-003370-10Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ligelizumab in Bullous Pemphigoid (BP), sponsored by Novartis. Started Oct 2012; status: completed.
02
Drugs
ligelizumab
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on 2012-003370-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003370-10.